<DOC>
	<DOCNO>NCT00828204</DOCNO>
	<brief_summary>The primary objective study evaluate safe effective use single-use autoinjector intramuscular ( IM ) delivery liquid Avonex® ( interferon beta-1a ) participants multiple sclerosis ( MS ) .</brief_summary>
	<brief_title>Evaluate Safe Effective Use Avonex® Single-Use Autoinjector Multiple Sclerosis Subjects</brief_title>
	<detailed_description>The Main Study 4-week treatment period consist 1 Avonex manual injection use prefilled syringe , follow 3 Avonex injection use single-use autoinjector . The Extension Study design provide continuation treatment Avonex single-use autoinjector eligible participant complete Main Study additional 12 week , obtain additional safety preference data Avonex single-use autoinjector . Participants enrol initial study protocol ( Initial Subject Subset ) ; study subsequently suspend . Changes make protocol ( include modification autoinjector needle ) , additional participant enrol ( Main Subject Subset ) .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>1 . Ability understand purpose risk study provide sign date informed consent authorization use protect health information ( PHI ) accordance national local subject privacy regulation . 2 . Must 18 65 year old , inclusive , time informed consent . 3 . Must currently selfadministering Avonex Prefilled Syringes treat MS must selfadministering Avonex Prefilled Syringes 12 week prior Screening Visit . 4 . In investigator 's opinion , subject must willing able selfadminister injection require protocol . 5 . Must speak English . 6 . All male subject female subject childbearing potential must practice effective contraception study . 1 . History seizure disorder unexplained blackout OR history seizure within 3 month prior Screening Visit . 2 . History suicidal ideation within 3 month prior Day 1 episode severe depression within 3 month prior Day 1 . Severe depression define episode depression require hospitalization , initiation antidepressant therapy , increase dose exist regimen antidepressant therapy . NOTE : Subjects receive ongoing antidepressant therapy exclude study unless dose increase within 3 month prior Screening Visit . 3 . Clinically significant local infection ( example cellulitis , abscess ) systemic infection ( pneumonia , septicemia ) , discretion Investigator . 4 . Known history Human Immunodeficiency Virus ( HIV ) . 5 . Known history , positive test result hepatitis C virus ( test hepatitis C virus antibody [ HCV Ab ] ) Hepatitis B virus ( test Hepatitis B Surface Antigen [ HBsAg ] and/or Hepatitis B Core Antibody [ HBcAb ] ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>